1. Home
  2. SWTX vs NHI Comparison

SWTX vs NHI Comparison

Compare SWTX & NHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWTX
  • NHI
  • Stock Information
  • Founded
  • SWTX 2017
  • NHI 1991
  • Country
  • SWTX United States
  • NHI United States
  • Employees
  • SWTX N/A
  • NHI N/A
  • Industry
  • SWTX Biotechnology: Pharmaceutical Preparations
  • NHI Real Estate Investment Trusts
  • Sector
  • SWTX Health Care
  • NHI Real Estate
  • Exchange
  • SWTX Nasdaq
  • NHI Nasdaq
  • Market Cap
  • SWTX 3.5B
  • NHI 3.5B
  • IPO Year
  • SWTX 2019
  • NHI 1991
  • Fundamental
  • Price
  • SWTX $46.67
  • NHI $71.94
  • Analyst Decision
  • SWTX Buy
  • NHI Buy
  • Analyst Count
  • SWTX 7
  • NHI 5
  • Target Price
  • SWTX $56.86
  • NHI $82.20
  • AVG Volume (30 Days)
  • SWTX 4.9M
  • NHI 260.6K
  • Earning Date
  • SWTX 05-09-2025
  • NHI 05-05-2025
  • Dividend Yield
  • SWTX N/A
  • NHI 5.00%
  • EPS Growth
  • SWTX N/A
  • NHI 3.74
  • EPS
  • SWTX N/A
  • NHI 3.16
  • Revenue
  • SWTX $219,670,000.00
  • NHI $343,615,000.00
  • Revenue This Year
  • SWTX $79.29
  • NHI $6.77
  • Revenue Next Year
  • SWTX $70.79
  • NHI $11.76
  • P/E Ratio
  • SWTX N/A
  • NHI $22.97
  • Revenue Growth
  • SWTX 730.42
  • NHI 7.49
  • 52 Week Low
  • SWTX $28.21
  • NHI $64.00
  • 52 Week High
  • SWTX $62.00
  • NHI $86.13
  • Technical
  • Relative Strength Index (RSI)
  • SWTX 60.85
  • NHI 39.88
  • Support Level
  • SWTX $46.21
  • NHI $71.75
  • Resistance Level
  • SWTX $46.77
  • NHI $73.26
  • Average True Range (ATR)
  • SWTX 0.15
  • NHI 1.35
  • MACD
  • SWTX -0.05
  • NHI -0.30
  • Stochastic Oscillator
  • SWTX 85.71
  • NHI 12.66

About SWTX SpringWorks Therapeutics Inc.

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.

About NHI National Health Investors Inc.

National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.

Share on Social Networks: